ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
주요 7개국의 부신피질암(ACC) 시장 규모는 2023년 약 2,240만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 상당한 성장이 예상됩니다. 주요 7개국 중 미국이 2023년 약 47%로 가장 큰 시장 점유율을 차지했으며, 2023년에는 EU 4개국과 영국이 820만 달러를 차지할 것으로 예상되며, 이는 상당한 CAGR로 증가할 것으로 예상됩니다. 유럽 국가 중 독일이 2023년 가장 큰 시장 점유율을 차지했으며 영국과 프랑스가 그 뒤를 이었습니다. 스페인은 같은 해 시장 점유율이 가장 낮습니다.
부신피질암(ACC)은 신장 위에 있는 부신피질에 발생하는 희귀한 침습성 암입니다. 위험 요인으로는 Li-Fraumeni, Beckwith-Wiedemann과 같은 유전 증후군, 유전적 돌연변이, 부신 종양의 가족력, 방사선 노출 등이 있습니다.
ACC는 종양의 크기와 전이에 따라 단계적으로 진행됩니다. 초기에는 종양이 국한되어 있지만, 후기에는 주변 조직으로의 침윤과 간, 폐, 뼈 등의 장기로의 원격 전이가 나타납니다. 병기 분류는 질병의 확산 정도를 평가하여 치료 전략의 지침이 됩니다.
ACC의 진단은 병력 청취와 부신 이상을 발견하기 위한 신체 검사로 시작하여 CT, MRI, PET 스캔과 같은 영상 검사로 종양과 그 범위를 시각화하고 혈액 및 소변 검사로 호르몬 수치와 대사 마커를 측정하는 등의 종합적인 접근이 필요합니다. 생검은 결정적이지만 위험성이 있기 때문에 반드시 시행되는 것은 아닙니다. 특히 가족력이 있는 경우 유전자 검사가 권장될 수 있습니다. 병기 결정은 치료 방침을 결정하는 데 도움이 되지만, 많은 경우 수술, 화학요법, 방사선 요법, 표적치료가 시행되며, 다학제 의료팀의 지원을 받습니다.
부신피질암(ACC)의 치료 옵션으로는 수술, 방사선 치료, 화학요법 등이 있으며, 임상시험을 통해 면역요법, 표적치료제 등 새로운 치료법이 계속 연구되고 있습니다. 수술, 특히 부신 절제술은 영향을 받은 부신을 주변 조직과 함께 제거하기 위해 흔히 시행됩니다. 방사선 치료는 고에너지 X선을 이용해 암세포를 죽이고, 화학요법은 약물을 이용해 암세포의 성장을 막는다. 면역 요법은 환자의 면역 체계에 작용하고 표적 치료는 특정 암세포를 공격합니다.
이 보고서는 주요 7개국의 부신피질암 시장을 조사했으며, 시장 개요와 함께 역학, 환자 동향, 새로운 치료법, 2034년까지 시장 규모 예측, 의료 미충족 수요 등을 제공합니다.
목차
제1장 주요 인사이트
제2장 보고서 서론
제3장 부신피질암(ACC) 시장 개요
제4장 역학과 시장 예측 조사 방법
제5장 주요 요약
제6장 중요 이벤트
제7장 질환 배경과 개요
서론
ACC 단계
원인과 리스크 요인
병태생리학
증상과 임상 소견
진단
치료와 관리
제8장 역학과 환자 인구
주요 조사 결과
전제와 근거 : 주요 7개국
주요 7개국의 ACC 유병 총수
미국
EU 4개국과 영국
일본
제9장 환자 동향
제10장 출시 치료법
제11장 새로운 치료법
제12장 부신피질암(ACC) : 시장 분석
주요 조사 결과
주요 시장 예측의 전제조건
시장 전망
주요 7개국의 ACC 전체 시장 규모
주요 7개국의 ACC 시장 규모(치료별)
미국의 ACC 시장 규모
EU 4개국과 영국의 ACC 시장 규모
일본의 ACC 시장 규모
제13장 주요 업계 리더의 견해
제14장 SWOT 분석
제15장 미충족 요구
제16장 시장 접근과 상환
미국
EU 4개국과 영국
일본
제17장 부록
제18장 DelveInsight의 서비스 내용
제19장 면책사항
제20장 DelveInsight에 대해
LSH
영문 목차
영문목차
Key Highlights:
The market size for ACC in the 7MM is anticipated to grow at a significant CAGR throughout the forecast period (2024-2034). This growth is attributed to the rising number of incident cases, the launch of emerging therapies, and increased awareness of ACC.
DelveInsight's analyst forecasts that around 27% of all Adrenocortical Carcinoma (ACC) cases in the 7MM originate from the United States. Based on our calculations, the EU4 and the UK together saw approximately six hundred incident cases of Adrenocortical Carcinoma (ACC) in 2023.
In the 7MM, the market mainly consisted of Adjuvant therapy (Mitotane +- Strepto), which generated nearly USD 3.69 million in 2023.
The total market size of the Adrenocortical Carcinoma (ACC) treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, EO2401 + Nivolumab, and others.
DelveInsight's "Adrenocortical Carcinoma (ACC) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Adrenocortical Carcinoma (ACC), historical and forecasted epidemiology and the Adrenocortical Carcinoma (ACC) market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Adrenocortical Carcinoma (ACC) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Adrenocortical Carcinoma (ACC) market size from 2020 to 2034. The report also covers current Adrenocortical Carcinoma (ACC) treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered:
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020-2034
Disease Understanding and Treatment Algorithm
Adrenocortical Carcinoma (ACC) Overview
ACC is a rare and aggressive cancer originating in the adrenal cortex above the kidneys. Risk factors include genetic syndromes like Li-Fraumeni and Beckwith-Wiedemann, inherited mutations, family history of adrenal tumors, and radiation exposure.
ACC progresses through stages based on tumor size and metastasis. Early stages involve confined tumors, while later stages may see invasion into nearby tissues or distant spread to organs like the liver, lungs, or bones. Staging guides treatment strategies by assessing disease extent.
Adrenocortical Carcinoma (ACC) Diagnosis
ACC diagnosis entails a comprehensive approach, starting with medical history review and physical examination to detect adrenal gland abnormalities. Imaging tests like CT, MRI, and PET scans visualize tumors and their extent, while blood and urine tests measure hormone levels and metabolic markers. Biopsies, though definitive, carry risk and aren't always performed. Genetic testing may be advised, particularly with familial history. Staging scans inform treatment decisions, often involving surgery, chemotherapy, radiation, or targeted therapy, supported by multidisciplinary healthcare teams.
Adrenocortical Carcinoma (ACC) Treatment
Treatment options for adrenocortical carcinoma (ACC) include surgery, radiation therapy, chemotherapy, and ongoing investigation into new treatments like immunotherapy and targeted therapy through clinical trials. Surgery, particularly adrenalectomy, is common for removing affected adrenal glands, potentially along with nearby tissues. Radiation therapy uses high-energy x-rays to kill cancer cells, while chemotherapy halts their growth with drugs. Immunotherapy engages the patient's immune system, and targeted therapy attacks specific cancer cells.
Adrenocortical Carcinoma (ACC) Epidemiology
As the market is derived using the patient-based model, the Adrenocortical Carcinoma (ACC) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Incident Cases of ACC, Stage-specific Incident Cases of ACC, Gender-specific Incident Cases of ACC, and Age-specific Incident Cases of ACC in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.
As per DelveInsight's estimations, the total incident cases of ACC in the 7MM were approximately 12 hundred in 2023 and are projected to increase during the forecast period, owing to the Increasing incidence trends over decades and advancements in diagnostic tools contribute to a better understanding and identification of this rare malignancy.
The total incident cases of ACC in the United States was approximately three hundred in 2023, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
Among the 7MM, EU4 and the UK accounted for nearly six hundred incident cases of ACC, and these cases are expected to increase during the forecast period (2023-2034).
Among EU4 and the UK, Germany had the highest incident population of Adrenocortical Carcinoma (ACC), with ~160 cases in 2023. On the other hand, Spain had the lowest incident population in EU4 and the UK in 2023.
In Japan, there were around two hundred incident cases of ACC in 2023. These cases are expected to increase at a significant CAGR.
Stage-specific Incident Cases of ACC are segmented into four distinct stages. In the US, the distribution of ACC cases across stages reveals that Stage III has the highest cases at 38%, followed by Stage IV at 27%, Stage II at 20%, and Stage I at 15%.
The gender-specific incident ACC cases within the 7MM indicated an approximate distribution of 40% in males and 60% in females.
The highest proportion of ACC cases was estimated in the 41-60 years (53%) in EU4 and the UK, while the least cases were in the age group <20 years (3%).
Adrenocortical Carcinoma (ACC) Drug Chapters
The drug chapter segment of the Adrenocortical Carcinoma (ACC) report encloses a detailed analysis of Adrenocortical Carcinoma (ACC) marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands Adrenocortical Carcinoma (ACC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Marketed Drugs
LYSODREN (Mitotane): HRA Pharma/Bristol-Myers Squibb
The adrenal cytotoxic agent mitotane (LYSODREN) has a central role in the systemic treatment of adrenocortical carcinoma (ACC), a rare and aggressive cancer of the adrenal glands. Mitotane has been evaluated and used for more than 60 years and, to date, is the only drug specifically approved for the treatment of ACC. Although ACC continues to be associated with a poor prognosis, mitotane has been shown to provide clinically significant benefit in a good proportion of ACC patients treated with the drug, both in advanced disease and adjuvant therapy settings. Approved in 1970 in the US and 2004 in the European Union, LYSODREN is listed among the 'Off-Patent, Off-Exclusivity Drugs without an Approved Generic' as outlined in the Orange Book.
Emerging Drugs
EO2401 + Nivolumab: Enterome/Bristol-Myers Squibb
EO2401, a novel immunotherapy developed by Enterome from their proprietary OncoMimics platform, consists of three synthetic peptides mimicking human Tumor-Associated Antigens: IL13Ra2, BIRC5/Survivin, and FOXM1. These peptides, derived from bacteria, target aggressive cancers like glioblastoma and adrenal tumors with minimal impact on healthy tissues. Nivolumab, an immune checkpoint inhibitor, aids T cell expansion and infiltration into tumors.
Adrenocortical Carcinoma (ACC) Market Outlook
Adrenocortical Carcinoma (ACC) has a diverse treatment classification associated with the disease landscape. The management of Adrenocortical Carcinoma (ACC) primarily revolves around the utilization of Adjuvant therapy (Mitotane +- Strepto) as needed.
The market for Adrenocortical Carcinoma (ACC) is expected to experience positive growth with the approval of potential drugs like EO2401 + Nivolumab, and others.
The Adrenocortical Carcinoma (ACC) market's total size in the 7MM reached approximately USD 22.4 million in 2023. Projections indicate a substantial growth during the forecast period.
Out of the 7MM, the United States dominated the market in 2023, representing the largest share at nearly 47%.
In 2023, EU4 and the UK captured an estimated USD 8.2 million, which is anticipated to increase at a substantial CAGR. Among the European countries, Germany covered the largest market share in 2023, followed by the UK and France. Spain accounted for the least market in the same year.
Japan alone represented approximately 16% of the total Adrenocortical Carcinoma (ACC) market in 2023, projected to increase at a substantial CAGR during the study period.
The total market size of the Adrenocortical Carcinoma (ACC) treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective therapies.
Adrenocortical Carcinoma (ACC) Drugs Uptake
This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, EO2401 + Nivolumab in the US is expected to be launched by 2026, with a peak share of 60%.
Further detailed analysis of emerging therapies drug uptake in the report...
Adrenocortical Carcinoma (ACC) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Adrenocortical Carcinoma (ACC) emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Adrenocortical Carcinoma (ACC) evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from University of Michigan, Ann Arbor, MI, US, Interfaith Medical Center, Brooklyn, NY, US, Wurzburg University Hospital, Wurzburg, Germany, Center Leon-Berard, Department of Medical Oncology, Lyon, France, University-Hospital of Padua, Padua, Italy, Catalan Institute of Oncology, Barcelona, Spain, University Hospital of Wales, Cardiff, United Kingdom, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, and others.
Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Adrenocortical Carcinoma (ACC) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Scope of the Report:
The report covers a segment of key events, an executive summary, descriptive overview of Adrenocortical Carcinoma (ACC), explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
A detailed review of the Adrenocortical Carcinoma (ACC) market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Adrenocortical Carcinoma (ACC) market.
Adrenocortical Carcinoma (ACC) Report Insights
Patient Population
Therapeutic Approaches
Adrenocortical Carcinoma (ACC) Pipeline Analysis
Adrenocortical Carcinoma (ACC) Market Size and Trends
What was the Adrenocortical Carcinoma (ACC) total market size, the market size by therapies, and market share (%) distribution in 2020, and how would it all look in 2034? What are the contributing factors for this growth?
What unmet needs are associated with the current treatment market of Adrenocortical Carcinoma (ACC)?
What are the patents of emerging therapies for Adrenocortical Carcinoma (ACC)?
Which drug is going to be the largest contributor by 2034?
What are the pricing variations among different geographies for approved and off-label therapies?
How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of Adrenocortical Carcinoma (ACC)? What will be the growth opportunities across the 7MM concerning the patient population of Adrenocortical Carcinoma (ACC)?
What is the historical and forecasted Adrenocortical Carcinoma (ACC) patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
Why do only limited patients appear for diagnosis?
Which country is more prevalent for Adrenocortical Carcinoma (ACC) and why?
What factors are affecting the diagnosis of the indication?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
What are the current options for treating Adrenocortical Carcinoma (ACC)? What are the current guidelines for treating Adrenocortical Carcinoma (ACC) in the US and Europe?
How many companies are developing therapies for treating Adrenocortical Carcinoma (ACC)?
How many emerging therapies are in the mid-stage and late stage of development for treating Adrenocortical Carcinoma (ACC)?
What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
What are the key designations that have been granted for the emerging therapies for Adrenocortical Carcinoma (ACC)?
Patient acceptability in terms of preferred treatment options as per real-world scenarios?
What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
What are the 7MM historical and forecasted markets of Adrenocortical Carcinoma (ACC)?
Reasons to Buy:
The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Adrenocortical Carcinoma (ACC) Market.
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
Frequently Asked Questions:
1. What is the forecast period covered in the report?
The Adrenocortical Carcinoma (ACC) Epidemiology and Market Insight report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of market dynamics and trends during this timeframe.
2. Who are the key players in the Adrenocortical Carcinoma (ACC) market?
The Adrenocortical Carcinoma (ACC) market is quite robust. The major players are Enterome, Corcept Therapeutics, Orphagen Pharmaceuticals, and others which are currently developing drugs for the treatment of Adrenocortical Carcinoma (ACC).
3. How is the market size estimated in the forecast report?
The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.
4. What is the key driver of the Adrenocortical Carcinoma (ACC) market?
The increase in the incident cases of Adrenocortical Carcinoma (ACC) and the launch of emerging therapies are attributed to be the key drivers for increasing Adrenocortical Carcinoma (ACC) market.
5. What is the expected impact of emerging therapies or advancements in Adrenocortical Carcinoma (ACC) treatment on the market?
Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the Adrenocortical Carcinoma (ACC) treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.
6. Does the report provide insights into the competitive landscape of the market?
The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Adrenocortical Carcinoma (ACC) market.
Table of Contents
1. Key Insights
2. Report Introduction
3. Adrenocortical Carcinoma (ACC) Market Overview at a Glance
3.1. Market Share (%) Distribution of ACC in 2020 by Therapies
3.2. Market Share (%) Distribution of ACC in 2034 by Therapies
4. Epidemiology and Market Forecast Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview
7.1. Introduction
7.2. Stages of ACC
7.3. Causes and Risk Factors
7.4. Pathophysiology
7.5. Symptoms and Clinical Presentations
7.6. Diagnosis
7.6.1. Diagnostic Algorithm
7.6.2. Diagnostic Guidelines
7.6.2.1. NCCN Guidelines for Patients: ACC
7.6.2.2. European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in Collaboration With the European Network for the Study of Adrenal Tumors
7.6.2.3. ESMO-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up of ACC
7.7. Treatment and Management
7.7.1. Treatment Algorithm
7.7.2. Treatment Guidelines
7.7.2.1. NCCN Guidelines for Patients: ACC
7.7.2.2. European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in Collaboration With the European Network for the Study of Adrenal Tumors
7.7.2.3. ESMO-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of ACC
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale: The 7MM
8.2.1. Incident Cases of ACC
8.2.2. Stage-specific Incident Cases of ACC
8.2.3. Gender-specific Incident Cases of ACC
8.2.4. Age-specific Incident Cases of ACC
8.3. Total Incident Cases of ACC in the 7MM
8.4. The United States
8.4.1. Total Incident Cases of ACC in the US
8.4.2. Stage-specific Incident Cases of ACC in the US
8.4.3. Gender-specific Incident Cases of ACC in the US
8.4.4. Age-specific Incident Cases of ACC in the US
8.5. EU4 and the UK
8.5.1. Total Incident Cases of ACC in EU4 and the UK
8.5.2. Stage-specific Incident Cases of ACC in EU4 and the UK
8.5.3. Gender-specific Incident Cases of ACC in EU4 and the UK
8.5.4. Age-specific Cases of ACC in EU4 and the UK
8.6. Japan
8.6.1. Total Incident Cases of ACC in Japan
8.6.2. Stage-specific Incident Cases of ACC in Japan
8.6.3. Gender-specific Incident Cases of ACC in Japan
8.6.4. Age-specific Incident Cases of ACC in Japan
9. Patient Journey
10. Marketed Therapies
10.1. LYSODREN (Mitotane): HRA Pharma/Bristol-Myers Squibb
